Indaptus Therapeutics, Inc.
INDP
$1.73
-$0.03-1.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.30% | -19.77% | -16.77% | -11.83% | -7.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.08% | 3.09% | -0.83% | 0.81% | -6.18% |
| Operating Income | -29.08% | -3.09% | 0.83% | -0.81% | 6.18% |
| Income Before Tax | -38.79% | -13.25% | -7.71% | -5.15% | 2.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.79% | -13.25% | -7.71% | -5.15% | 2.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.79% | -13.25% | -7.71% | -5.15% | 2.60% |
| EBIT | -29.08% | -3.09% | 0.83% | -0.81% | 6.18% |
| EBITDA | -29.08% | -3.10% | 0.83% | -0.82% | 6.18% |
| EPS Basic | 43.64% | 34.25% | 27.74% | 16.19% | 11.67% |
| Normalized Basic EPS | 43.64% | 34.25% | 27.74% | 16.19% | 11.67% |
| EPS Diluted | 43.64% | 34.25% | 27.74% | 16.19% | 11.67% |
| Normalized Diluted EPS | 43.64% | 34.25% | 27.74% | 16.19% | 11.67% |
| Average Basic Shares Outstanding | 189.76% | 97.85% | 49.88% | 28.06% | 11.38% |
| Average Diluted Shares Outstanding | 189.76% | 97.85% | 49.88% | 28.06% | 11.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |